Gland Pharma Analyst Review May 2026

This Gland Pharma analyst review for May 2026 covers the key data investors need for GLAND at its current price of Rs 2,149.00. Gland Pharma (NSE: GLAND) is India’s largest injectable pharma company by CDMO revenue with a market capitalisation of approximately Rs 30,781 crore, a subsidiary of Fosun Pharma (China). The analyst consensus target of Rs 2,500 implies meaningful upside, and this Gland Pharma analyst review examines technical levels, business performance, valuation, and key risks that will determine whether GLAND achieves that target through FY27.

Click Here – Get Free Investment Predictions

Gland Pharma Company Snapshot May 2026

Gland Pharma specialises in sterile injectable manufacturing for regulated markets including the US, Europe, and Australia. Revenue grew 22 percent YoY in Q3 FY26 driven by complex generics for the US market. The table below summarises the key data referenced in this Gland Pharma analyst review.

Parameter	Value
NSE Ticker	GLAND
Sector	Pharmaceuticals – Injectable CDMO
CMP (May 2026)	Rs 2,149.00
52 Week High	Rs 2,164.40
52 Week Low	Rs 1,452.20
Market Cap	Rs 30,781 Crore
Trailing P/E	35x
Analyst Consensus Target	Rs 2,500
Bull Case Target	Rs 3,100
Bear Case Target	Rs 1,700

Analyst Insight in This Gland Pharma Analyst Review

Senior Research Analyst Ankit Jaiswal flags Gland Pharma as a stock to watch in May 2026. At Rs 2,149.00, Ankit Jaiswal identifies key support in the Rs 1481 to Rs 2042 band and resistance near Rs 2278. He suggests watching Gland Pharma for a potential move toward Rs 2,500, subject to Pharmaceuticals – Injectable CDMO sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Gland Pharma analyst review and does not constitute a trade recommendation.

Technical Analysis in This Gland Pharma Analyst Review

At Rs 2,149.00, GLAND is trading within its 52-week band of Rs 1,452.20 to Rs 2,164.40. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 1481 to Rs 2042 band while resistance is seen in the Rs 2278 to Rs 2324 zone. A sustained move above Rs 2278 could open the path toward the analyst consensus target of Rs 2,500.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 1481 to Rs 2042 – investors tracking this Gland Pharma analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for GLAND.
• Resistance Zone: Rs 2278 to Rs 2324 – a sustained close above Rs 2278 would be a positive breakout signal worth flagging in this Gland Pharma analyst review.
• Medium-Term Target: The analyst consensus of Rs 2,500 represents the base-case upside scenario identified in this Gland Pharma analyst review.

Business Segment Analysis

Sterile Injectable CDMO (US and Europe Focus)

This is the primary revenue and margin driver for Gland Pharma, directly supporting the earnings trajectory toward the consensus target of Rs 2,500.

Branded Injectable Generics (India and Emerging Markets)

This segment adds scale and diversification to Gland Pharma’s business model and is a meaningful EPS contributor through FY27 and FY28.

Specialty Biologics and Biosimilar Manufacturing

This represents the medium-term growth frontier for Gland Pharma and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Gland Pharma Analyst Review

At Rs 2,149.00, Gland Pharma trades at a trailing P/E of 35x. This Gland Pharma analyst review presents three valuation scenarios: a bull case of Rs 3,100 on strong earnings delivery and sector tailwinds, a base case of Rs 2,500 at analyst consensus, and a bear case of Rs 1,700 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Gland Pharma analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 3,100	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 2,500	Moderate growth, analyst consensus estimate
Bear Case	Rs 1,700	Earnings miss or macro headwinds

Trade Outlook for Gland Pharma

Based on the technical and fundamental analysis in this Gland Pharma analyst review, investors might watch GLAND near the support zone of Rs 1481 to Rs 2042 for potential opportunities. A flag above Rs 2278 could suggest improving momentum toward Rs 2,500. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Gland Pharma in FY27

A well-rounded Gland Pharma analyst review must assess downside risks. Key risks for Gland Pharma include a macro slowdown affecting Pharmaceuticals – Injectable CDMO sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in GLAND.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Gland Pharma Analyst Review Verdict for 2026

This Gland Pharma analyst review concludes that at Rs 2,149.00, GLAND offers a defined risk-reward with a consensus target of Rs 2,500. The 52-week range of Rs 1,452.20 to Rs 2,164.40 provides context on the current entry point. Use this Gland Pharma analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on GLAND.

Frequently Asked Questions: Gland Pharma Analyst Review 2026

What is the analyst target for Gland Pharma in 2026?

The analyst consensus target is Rs 2,500, with a bull case of Rs 3,100 and a bear case of Rs 1,700. Monitor Q1 FY27 earnings for confirmation as highlighted in this Gland Pharma analyst review.

Is Gland Pharma a good investment at Rs 2,149.00?

At Rs 2,149.00 with a P/E of 35x and a consensus target of Rs 2,500, this Gland Pharma analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Injectable CDMO sector. Always consult a SEBI-registered advisor before investing.

What is Gland Pharma’s 52-week high and low?

The 52-week high is Rs 2,164.40 and the 52-week low is Rs 1,452.20. At Rs 2,149.00, GLAND is positioned within this range as noted in this Gland Pharma analyst review.

What are the key risks for Gland Pharma?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Injectable CDMO sector as assessed in this Gland Pharma analyst review.

Where can I track live data for Gland Pharma?

Track Gland Pharma’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Gland Pharma analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.